Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive Carcinoma of Breast”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT05085626
What this trial is testing

Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer

Who this might be right for
Advanced HER2 Negative Breast CarcinomaHRD+Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 40
Testing effectiveness (Phase 2)Ended earlyNCT01702558
What this trial is testing

A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC)

Who this might be right for
Breast CancerGastric Cancer
Hoffmann-La Roche 182
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07152782
What this trial is testing

T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis

Who this might be right for
Breast Cancer With Brain MetastasisHER2-positive Breast Cancer
Fudan University 202
Early research (Phase 1)Study completedNCT05364255
What this trial is testing

Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833

Who this might be right for
ER-positive, HER2-negative Breast Cancer
AstraZeneca 6
Testing effectiveness (Phase 2)Looking for participantsNCT05573126
What this trial is testing

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Who this might be right for
Hormone Receptor-positive Breast CancerHormone Receptor Positive HER-2 Negative Breast CancerMetastatic Breast Cancer
Ellipses Pharma 95
Early research (Phase 1)UnknownNCT05504213
What this trial is testing

A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer

Who this might be right for
Breast Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 224
Testing effectiveness (Phase 2)Study completedNCT02954055
What this trial is testing

MEtronomic TrEatment Option in Advanced bReast cAncer

Who this might be right for
Breast Cancer
ETOP IBCSG Partners Foundation 140
Testing effectiveness (Phase 2)Looking for participantsNCT06797635
What this trial is testing

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Who this might be right for
Breast NeoplasmsBreast Cancer
Merck Sharp & Dohme LLC 372
Testing effectiveness (Phase 2)Study completedNCT00777101
What this trial is testing

Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer

Who this might be right for
Advanced Breast CancerBreast Cancer
Puma Biotechnology, Inc. 233
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07701941
What this trial is testing

Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

Who this might be right for
Hormone Receptor PositiveHER2-low or HER2-ultralowUnresectable or Metastatic Breast Cancer
Daiichi Sankyo 220
Testing effectiveness (Phase 2)Active Not RecruitingNCT03359954
What this trial is testing

Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer

Who this might be right for
Estrogen Receptor PositiveHER2/Neu NegativeInvasive Breast Carcinoma+1 more
M.D. Anderson Cancer Center 25
Large-scale testing (Phase 3)UnknownNCT04858529
What this trial is testing

Neoadjuvant TCHP Versus THP in Patients With HER2-positive Breast Cancer (neoCARHP Study)

Who this might be right for
Neoadjuvant Therapies for HER2+ Breast Cancer
Guangdong Provincial People's Hospital 774
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07539753
What this trial is testing

Brain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain Metastases

Who this might be right for
Breast CancerBrain MetastasesHR+/HER2- Breast Cancer
Nanfang Hospital, Southern Medical University 46
Testing effectiveness (Phase 2)Looking for participantsNCT07112053
What this trial is testing

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Metastatic HER2-Negative Breast CarcinomaMetastatic Hormone Receptor-Positive Breast Carcinoma
University of Washington 40
Large-scale testing (Phase 3)Looking for participantsNCT06846437
What this trial is testing

JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer

Who this might be right for
Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants
Shanghai JMT-Bio Inc. 228
Testing effectiveness (Phase 2)UnknownNCT04605575
What this trial is testing

Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast CancerPyrotinibBreast Diseases+2 more
Sun Yat-sen University 208
Testing effectiveness (Phase 2)Looking for participantsNCT01042379
What this trial is testing

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Who this might be right for
Breast NeoplasmsBreast CancerBreast Tumors+8 more
QuantumLeap Healthcare Collaborative 5,000
Testing effectiveness (Phase 2)Looking for participantsNCT05891561
What this trial is testing

Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer

Who this might be right for
Breast Cancer
Shanghai Jiao Tong University School of Medicine 120
Large-scale testing (Phase 3)Active Not RecruitingNCT03725059
What this trial is testing

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

Who this might be right for
Breast Cancer
Merck Sharp & Dohme LLC 1,240
Large-scale testing (Phase 3)Looking for participantsNCT07673029
What this trial is testing

A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
GeneQuantum Healthcare (Suzhou) Co., Ltd. 228
Next Page